Table 1.

Pros and Cons of different pluripotent sources for stem cell therapy in stroke patients

	Pros	Cons
Autologous iPSCs	- No need for immunosupression - Ethically non-controversial	- Long time for generation, validation and expansion - Old age of the patient as a donor for fibroblasts
Allogeneic iPSCs (HLA matched)	- Minimal need (?) for immunosupression - Ethically non-controversial - Freely available on demand - Easily expandable	- High expensive to generate and validate all HLA haplotypes. - Need for special facilities for storage and expansion of lines
ESCs	- Less genetic manipulation - Freely available on demand - Easily expandable	- Ethically controversial